Free Trial

Adaptive Biotechnologies Q2 2024 Earnings Report

Adaptive Biotechnologies logo
$6.08 -0.44 (-6.75%)
(As of 02:52 PM ET)

Adaptive Biotechnologies EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.33
Beat/Miss
Beat by +$0.02
One Year Ago EPS
-$0.33

Adaptive Biotechnologies Revenue Results

Actual Revenue
$43.19 million
Expected Revenue
$38.63 million
Beat/Miss
Beat by +$4.56 million
YoY Revenue Growth
-11.70%

Adaptive Biotechnologies Announcement Details

Quarter
Q2 2024
Time
After Market Closes

Conference Call Resources

"X-Ray Vision" could find thousands of hidden market opportunities (Ad)

Let me show you how I trade with “X-Ray vision.” You see, most “trend” traders only use one trend filter when looking for an optimal buy signal. And that can be a big mistake because you can’t see if you’re in a “True Trend.” But my newest trading tool is designed to only target the best, most stable stocks… Using 3 trend filters… which are these green, yellow, and red lines.

Just tap here to join the presentation.

Adaptive Biotechnologies Earnings Headlines

Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
Adaptive Biotechnologies: Making Some Progress
See More Adaptive Biotechnologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adaptive Biotechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adaptive Biotechnologies and other key companies, straight to your email.

About Adaptive Biotechnologies

Adaptive Biotechnologies (NASDAQ:ADPT), a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

View Adaptive Biotechnologies Profile

More Earnings Resources from MarketBeat

Upcoming Earnings